Jonathan Miller
Stock Analyst at Evercore ISI
(1.78)
# 3,614
Out of 4,547 analysts
53
Total ratings
51%
Success rate
0.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FDMT 4D Molecular Therapeutics | Maintained: Buy | $23 | $11.10 | +107.21% | 5 | Jul 20, 2026 | |
| EDIT Editas Medicine | Maintained: Buy | $15 | $2.76 | +443.48% | 3 | May 27, 2026 | |
| NKTX Nkarta | Maintained: Buy | $9 | $2.54 | +254.33% | 1 | May 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Buy | $74 → $76 | $47.54 | +59.87% | 2 | May 11, 2026 | |
| JANX Janux Therapeutics | Maintained: Buy | $23 → $22 | $16.07 | +36.90% | 5 | May 11, 2026 | |
| TRDA Entrada Therapeutics | Maintained: Buy | $25 | $6.33 | +294.94% | 2 | May 5, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $14 → $16 | $11.18 | +43.11% | 5 | Apr 28, 2026 | |
| ERAS Erasca | Maintained: Buy | $11 → $24 | $19.09 | +25.72% | 2 | Apr 28, 2026 | |
| PMVP PMV Pharmaceuticals | Maintained: Buy | $18 → $4 | $1.31 | +205.34% | 2 | Apr 13, 2026 | |
| AURA Aura Biosciences | Maintained: Buy | $13 → $15 | $7.00 | +114.29% | 3 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 → $48 | $23.83 | +101.43% | 3 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 → $13 | $1.66 | +683.13% | 2 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $28.83 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $110 → $19 | $8.22 | +131.14% | 3 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.25 | - | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $4.82 | +24.48% | 1 | Nov 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $13.23 | -9.30% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $6.84 | n/a | 2 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.44 | n/a | 3 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.58 | n/a | 1 | Sep 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.31 | n/a | 2 | May 5, 2021 |
4D Molecular Therapeutics
Jul 20, 2026
Maintained: Buy
Price Target: $23
Current: $11.10
Upside: +107.21%
Editas Medicine
May 27, 2026
Maintained: Buy
Price Target: $15
Current: $2.76
Upside: +443.48%
Nkarta
May 18, 2026
Maintained: Buy
Price Target: $9
Current: $2.54
Upside: +254.33%
CRISPR Therapeutics AG
May 11, 2026
Maintained: Buy
Price Target: $74 → $76
Current: $47.54
Upside: +59.87%
Janux Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $23 → $22
Current: $16.07
Upside: +36.90%
Entrada Therapeutics
May 5, 2026
Maintained: Buy
Price Target: $25
Current: $6.33
Upside: +294.94%
Intellia Therapeutics
Apr 28, 2026
Maintained: Hold
Price Target: $14 → $16
Current: $11.18
Upside: +43.11%
Erasca
Apr 28, 2026
Maintained: Buy
Price Target: $11 → $24
Current: $19.09
Upside: +25.72%
PMV Pharmaceuticals
Apr 13, 2026
Maintained: Buy
Price Target: $18 → $4
Current: $1.31
Upside: +205.34%
Aura Biosciences
Apr 13, 2026
Maintained: Buy
Price Target: $13 → $15
Current: $7.00
Upside: +114.29%
Mar 9, 2026
Reiterated: Buy
Price Target: $33 → $48
Current: $23.83
Upside: +101.43%
Mar 9, 2026
Maintained: Buy
Price Target: $1 → $13
Current: $1.66
Upside: +683.13%
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $28.83
Upside: -
Feb 25, 2026
Maintained: Buy
Price Target: $110 → $19
Current: $8.22
Upside: +131.14%
Jan 26, 2026
Maintained: Buy
Price Target: n/a
Current: $4.25
Upside: -
Nov 28, 2025
Maintained: Buy
Price Target: $6
Current: $4.82
Upside: +24.48%
Sep 30, 2025
Maintained: Buy
Price Target: $12
Current: $13.23
Upside: -9.30%
Oct 2, 2024
Rated: Buy
Price Target: n/a
Current: $6.84
Upside: n/a
Sep 16, 2024
Maintained: Buy
Price Target: n/a
Current: $4.44
Upside: n/a
Sep 2, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $1.58
Upside: n/a
May 5, 2021
Reiterated: Buy
Price Target: n/a
Current: $8.31
Upside: n/a